KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Total Liabilities (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Total Liabilities for 16 consecutive years, with $2.5 billion as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 45.71% to $2.5 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.5 billion through Dec 2025, up 45.71% year-over-year, with the annual reading at $2.5 billion for FY2025, 45.71% up from the prior year.
  • Total Liabilities for Q4 2025 was $2.5 billion at Halozyme Therapeutics, up from $1.7 billion in the prior quarter.
  • The five-year high for Total Liabilities was $2.5 billion in Q4 2025, with the low at $899.0 million in Q1 2021.
  • Average Total Liabilities over 5 years is $1.5 billion, with a median of $1.7 billion recorded in 2023.
  • The sharpest move saw Total Liabilities surged 115.02% in 2021, then fell 7.02% in 2023.
  • Over 5 years, Total Liabilities stood at $907.5 million in 2021, then surged by 84.22% to $1.7 billion in 2022, then fell by 1.33% to $1.6 billion in 2023, then rose by 3.04% to $1.7 billion in 2024, then skyrocketed by 45.71% to $2.5 billion in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $2.5 billion, $1.7 billion, and $1.7 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.